e-learning
resources
Munich 2006
Sunday 03.09.2006
Therapies and management in chronic airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of infliximab on systemic features in patients with COPD suffering from cachexia
E. C. Creutzberg, H. J. Pennings, M. T. J. Groenen, E. F. M. Wouters (Horn, Maastricht, Netherlands)
Source:
Annual Congress 2006 - Therapies and management in chronic airway diseases
Session:
Therapies and management in chronic airway diseases
Session type:
E-Posters in free access
Number:
689
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. C. Creutzberg, H. J. Pennings, M. T. J. Groenen, E. F. M. Wouters (Horn, Maastricht, Netherlands). Effects of infliximab on systemic features in patients with COPD suffering from cachexia. Eur Respir J 2006; 28: Suppl. 50, 689
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Effects of infliximab on local and systemic inflammation in patients with COPD suffering from cachexia
Source: Eur Respir J 2006; 28: Suppl. 50, 105s
Year: 2006
Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011
Effect of ABPA treatment in severe asthma patients with acute and relapsed disease
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 721s
Year: 2005
Systemic inflammation in patients with COPD and anemia of chronic disease
Source: International Congress 2019 – Airway diseases and blood cells
Year: 2019
Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019
Treating systemic effects of COPD
Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Year: 2009
Treating systemic effects of COPD
Source: Annual Congress 2012 - PG9 Progress on the treatment of COPD
Year: 2012
Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations
Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019
Year: 2019
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015
Markers of T2-inflammation in patients with severe asthma and concomitant COPD
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
Source: Eur Respir J 2001; 17: 337-342
Year: 2001
Association of systemic inflammation with clinical recovery in patients with acute exacerbation of COPD
Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases
Year: 2011
Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Influence of statin therapy on exacerbation frequency in patients with COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009
Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis
Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation
Year: 2012
Severe outcomes of COVID-19 among patients with COPD and asthma
Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020
Year: 2021
Effect of azithromycin treatment on inflammation in COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept